Expression of fibroblast growth factor by F9 teratocarcinoma cells as a function of differentiation

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

| Citation       | Braunhut, Susan J., Lorraine J. Gudas, Tsutomu Kurokawa, Joachim Sasse, and Patricia A. D’Amore. Expression of fibroblast growth factor by F9 teratocarcinoma cells as a function of differentiation. 1989. Journal of Cell Biology 108(6):2467-76. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Citable link   | http://nrs.harvard.edu/urn-3:HUL.InstRepos:36303927                                                                                                                                                                                                       |
| Terms of Use   | This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA |
Expression of Fibroblast Growth Factor by F9 Teratocarcinoma Cells as a Function of Differentiation

Susan J. Braunhut,*§ Lorraine J. Gudas,‡ Tsutomu Kurokawa,§ Joachim Sasse,§ and Patricia A. D'Amore§

* Department of Ophthalmology, Children's Hospital, Boston, Massachusetts 02115; and Departments of ‡Biological Chemistry and Molecular Pharmacology, §Surgery, and §Pathology, Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts 02115

Abstract. F9 teratocarcinoma stem cells treated with retinoic acid (RA) and dibutyryl cAMP (but2 cAMP) differentiate into embryonic parietal endoderm. Using heparin-affinity chromatography, endothelial cell proliferation assays, immunoprecipitation, and Western analysis with antibodies specific for acidic and basic fibroblast growth factors (FGFs), we detected biologically active FGF in F9 cells only after differentiation. A bovine basic FGF cDNA probe hybridized to 2.2-kb mRNAs in both F9 stem and parietal endoderm cells and to a 3.8-kb mRNA in F9 stem cells. A genomic DNA probe for acidic FGF hybridized to a 5.8–6.0-kb mRNA in both F9 stem and parietal endoderm cells, and to a 6.0–6.3-kb mRNA only in parietal endoderm cells. Although these FGF mRNAs were present in the stem cells, we could find no evidence that F9 stem cells synthesize FGFs, whereas differentiated F9 cells synthesized both acidic and basic FGF-like proteins. We conclude that biologically active factors with properties characteristic of acidic and basic FGF are expressed by F9 parietal endoderm cells after differentiation. Differentiating embryonic parietal endoderm thus may serve as a source of FGF molecules in the developing blastocyst, where these factors appear to play a central role in subsequent embryogenesis.

F9 murine teratocarcinoma stem cells are analogous in many respects to the cells of the inner cell mass of the mouse blastocyst (Martin, 1980). Within 3–4 d after treatment of monolayer cultures with retinoic acid (RA)† and dibutyryl cAMP (but2 cAMP), F9 stem cells irreversibly differentiate into a homogeneous population of cells indistinguishable from extraembryonic parietal endoderm (Strickland et al., 1980). These parietal endoderm cells synthesize plasminogen activator, laminin, type IV collagen, and membrane-bound heparan sulfate (Strickland et al., 1980; Wang et al., 1985; Kapoor and Prehm, 1983), keratins (Vasseur et al., 1985; Singer et al., 1986), and H-2 antigen (Croce et al., 1981). This system has been used by a number of workers as a model for the study of the differentiation of embryonic inner cell mass cells and has provided a means for identifying the biochemical and molecular events involved in this process.

Another application for this system has been the study of tumorigenesis. Teratocarcinoma stem cell lines characteristically undergo continuous proliferation in vitro and are tumorigenic in vivo, whereas the differentiated cells are not tumorigenic (Martin, 1980). These observations led investigators to compare the growth requirements of stem and differentiated cells in a number of teratocarcinoma cell lines (Heath et al., 1981; Gudas et al., 1983; Heath and Isacke, 1984). Several lines acquire specific growth factor receptors as a function of differentiation. For example, differentiated PC-13 and OC-15S1 cells bind increased amounts of epidermal growth factor (EGF) (Rees et al., 1979) and insulin (Heath et al., 1981) after differentiation. These studies suggest that the inability of these differentiated cells to form tumors correlates with an increased responsiveness to external signals of growth control.

In contrast, undifferentiated teratocarcinoma stem cells were reported to secrete growth factors. For example, PSA-L-G and F9 stem cells secrete a platelet-derived growth factor (PDGF)-like molecule (Gudas et al., 1983; Rizzino and Bowen-Pope, 1985). Another undifferentiated teratocarcinoma cell line, PC13, secretes an uncharacterized growth factor, embryonal carcinoma–derived growth factor, which has been shown to stimulate the proliferation of fibroblasts and the PC13 differentiated cells (Heath and Isacke, 1984). Both of these growth factors are secreted by stem cells and are either absent or present at lower levels in the media of the corresponding differentiated cells. Although it is not

1. Abbreviations used in this paper: a, acidic; b, basic; but2 cAMP, dibutyryl cAMP; EGF, epidermal growth factor; FGF, fibroblast growth factor; PDGF, platelet-derived growth factor; RA, retinoic acid; TGF-β, transforming growth factor beta.

Dr. Sasse's present address is Shriners Hospital, Department of Immunology, Tampa, Florida 33612-4799. Dr. Kurokawa's present address is Takeda Chemical Industries, Ltd., Yodogawa-Ku, Osaka, 532, Japan.
known what roles growth factors play in the developing embryo, evidence is rapidly emerging that dramatic changes occur in the profiles of growth factor production as a function of differentiation. We have examined the F9 stem and differentiation teratocarcinoma cells for the presence of another well-characterized class of cellular mitogens, the fibroblast growth factors (FGFs).

In recent years, FGFs have been identified in numerous normal tissues, and in association with a number of solid tumors (for reviews see Folkman and Klagsbrun, 1987; D’Amore and Braunhut, 1988). These factors have been purified to homogeneity using their unusual affinity for the glycosaminoglycan heparin (Shing et al., 1988). It has emerged that there are two classes of heparin-binding growth factors, class 1 and class 2, which are synonymous with acidic (a) and basic (b) FGF, respectively.

FGF has been identified in many tissues, including pituitary (Bohlen et al., 1984), placenta (Gospodarowicz et al., 1985a), corpus luteum (Gospodarowicz et al., 1985b), adrenal gland (Gospodarowicz et al., 1986), and kidney (Baird et al., 1985). Furthermore, endothelial cell mitogens associated with a number of tumors, including a rat chondrosarcoma, a human melanoma, and a hepatoma, are structurally related if not identical to bFGF (Klagsbrun et al., 1986). aFGF appears to have a more limited distribution and has been found in hypothalamus (Klagsbrun and Shing, 1985), retina (D’Amore and Klagsbrun, 1984), testis (Feig et al., 1983), and bone (Hauschka et al., 1986), and in association with some human tumor cell lines (Lobb et al., 1986).

The amino acid sequence for bovine bFGF is known (Esch et al., 1985) and 70- and 3.7-kb mRNA transcripts have been identified in bovine adrenal cortex-derived and bovine brain-derived capillary endothelial cells (Schweigerer et al., 1987a). Rodent tissues screened with a cDNA encoding rat bFGF revealed a single 60-kb mRNA in rat hypothalamus and brain cortex tissue (Shimasaki et al., 1988), and human fibroblasts express mRNA transcripts encoding bFGF of 7, 3.7, 2.2, and 1.5 kb in size (Steinfeld et al., 1988).

The amino acid sequence of aFGF has been determined (Gimenez-Gallego et al., 1985) and a single, 4.8-kb mRNA transcript encoding aFGF has been reported in human brain stem using Northern analysis (Jaye et al., 1986). There are few reports in the literature on the sizes of the transcripts encoding aFGF in other species.

Factors with properties similar but not identical to the FGFs have been identified in F9 cells (van Veggel et al., 1987; Rizzino et al., 1988) and may relate to the presence in F9 cells of mRNA transcripts encoding two oncogenes in the FGF family, ets-1 and int-2 (Yoshida et al., 1988). The biologic properties of the protein products of these genes are now known, but the message sizes are distinctly different from mRNA encoding the FGFs (Yoshida et al., 1988). F9 stem cells express high amounts of a 3.0-kb transcript for ets-1, which decreases after differentiation. Conversely, mRNAs encoding int-2 of 2.9, 2.7, 1.8, and 1.6 kb are detected in greater abundance in F9 parietal endoderm cells (Yoshida et al., 1988). The significance of the differential expression of mRNAs encoding these two oncogenes in F9 cells and their presence during early embryogenesis is not known. In this report, we examine the expression of FGF in F9 cells as a function of differentiation.

Materials and Methods

Materials

RA (all-trans) and most other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO). [35S]Methionine (1,131 Ci/mmol) was obtained from New England Nuclear (Boston, MA). The cDNA clones for basic and acidic FGF were generously provided by Dr. John Fidder (California Biotechnology, Inc., Mountain View, CA). Heparin-Sepharose was purchased from Pharmacia Fine Chemicals (Uppsala, Sweden). Reagents used for Na2DodSO4 PAGE were from Bio-Rad Laboratories (Richmond, CA). Tissue culture reagents were from Gibco Laboratories (Grand Island, NY).

Cell Culture

The F9 teratocarcinoma stem cells were grown on gelatinized tissue culture (Falconn Labware, Oxnard, CA) dishes in DME containing 10% heat-inactivated calf serum. For differentiation studies, cells were treated with RA (1 x 10-5 M), but2 cAMP (2.5 x 10-4 M), and theophylline (400 #M) for at least 72 h. Details of this differentiation protocol have been described previously (Wang et al., 1985).

Bovine capillary endothelial cells from adrenal cortex were provided by Dr. J. Folkman (The Children’s Hospital, Boston, MA). The endothelial cells were grown in DME containing 10% calf serum and cells were maintained on gelatinized tissue culture dishes from Nunc (Vanguard International, NJ). Endothelial cell proliferation studies were conducted by plating the cells at 1 x 105 per well in 24 multwell gelatinized dishes. The cells were allowed to attach overnight and washed, and 0.5 ml of fresh media was added with aliquots of fractions to be tested. 72 h later cells were washed and trypsinized and cell numbers were determined electronically with a counter (Couler Electronics, Inc., Hialeah, FL). The SK hepatoma cells, provided by Dr. Michael Klagbrun (The Children's Hospital, Boston, MA), were cultured in DME plus 10% calf serum.

Preparation of Cell Extracts

F9 stem and parietal endoderm cells were harvested from monolayer cultures by rinsing in cold PBS three times, followed by trypsinization, or in some experiments removal by scraping with a rubber policeman. Approximately 1 x 105-1 x 106 stem or RA-treated cells were harvested, depending on the experiment. Cells were washed again in PBS, centrifuged at 2,000 rpm for 10 min at 4°C, resuspended in a small volume (0.6-1.2 ml) of 1 M NaCl and 0.01 M Tris-HCl buffer, pH 7.6, and sonicated on ice (model W370; Heat Systems-Ultrasonics Inc., Farmingdale, NY; microprobe setting 2, twice for 10 s each). Cell extracts were then incubated for 1 h on ice in the presence or absence of protease inhibitors: 1 mg/ml leupeptin, 2.75 mg/ml pepstatin, and 175 mg/ml PMSF as indicated. After centrifugation at 10,000 rpm for 5 min at 4°C in a microfuge, the supernatant, in a volume of ~0.4-1.0 ml, was stored at -20°C before being assayed for mitogenic activity. In some experiments, affinity-purified antisera to porcine transforming growth factor (TGF-β) (1:10,000) (R&D Systems, Inc., Minneapolis, MN) was added directly to the extract or pooled fractions for 1 h at 4°C. Staphylococcal protein A-Sepharose was then added to the suspension and the mixture incubated overnight at 4°C with mixing, the beads were pelleted at 1,000 g, and the supernatants were assayed in parallel with an untreated extract for their effect on capillary endothelial cell growth.

Preparation of Conditioned Media

Conditioned media were prepared from F9 stem and parietal endoderm cell cultures that had been treated with RA plus but2 cAMP for 4 d by washing ~5 x 109 F9 cells three times with sterile PBS. The cells were then placed in DME plus 10% calf serum with RA and but2 cAMP for 48 h. Approximately 14 ml of DME was used for each flask of 5 x 107 cells. The medium was then centrifuged at 5,000 rpm for 12 min at 4°C and frozen at -20°C.

Column Chromatography

Cell extracts, prepared as described above, were diluted to 0.1 M NaCl, in PBS buffer, pH 7.6, and applied to a column of heparin-Sepharose (1 x 20 cm, 10 ml) that had been previously washed with 3.0 M NaCl and PBS buffer, pH 7.6, and reequilibrated with PBS buffer, pH 7.6. After loading the sample, the column was clamped overnight at 4°C to allow for maximal binding. The column was then washed with 3 column vol of PBS buffer, pH
tioned media, the conditioned media or an equivalent volume of uncondi-
tioned media were subjected to heparin-Sepharose chromatography by load-
ing the entire sample at a rate of 10 ml/h onto a heparin-Sepharose column
(1.5 x 30 cm, 40 ml) prewashed and equilibrated as described above. The
3T3 cell stimulatory activities were separated on the heparin-Sepharose
column with a gradient of 0.1-2.0 M NaCl, or in some cases, up to 3.0 M
NaCl in PBS buffer, pH 7.6, at a flow rate of 10 ml/h. Column fractions were
screened for their ability to stimulate DNA synthesis in quiescent BALB/c
3T3 cells by established methods (Klagsbrun et al., 1977). Briefly, a small
aliquot (5-50 μl) of each fraction was added to contact-inhibited and nu-
trient-starved monolayers of 3T3 cells in the presence of methyl-[3H]thy-
midine. 48 h later, the stimulatory DNA synthesis in the 3T3 cultures was
determined by measuring the amount of [3H]thymidine incorporated into
TCA-precipitable material by scintillation spectrometry (Klagsbrun et at.,
1977).

Radiolabeling of Intracellular Proteins

To determine if FGF was being actively synthesized by F9 cells after
differentiation, 4-h labeling studies were conducted using F9 stem and fully
differentiated F9 parietal endoderm cells. The parietal endoderm cells were
obtained by growing F9 teratocarcinoma stem cells in DME containing 10%
calf serum with RA (1 × 10-6 M), butyryl cAMP (2.5 × 10-4 M) and theoph-
ylline (400 μM) for 5 d, with refeeding on day three. For labeling, the cells
were rinsed with methionine-free DME and then incubated for 4 h in 16
ml/dish of medium consisting of methionine-free DME, 5% dialyzed calf serum,
and [35S]methionine (1,094 Ci/mmol) at 5 μCi/ml. After 4 h at
37°C, the radiolabeling medium was removed, the cells were washed three
times with cold PBS, protease inhibitors were added, and cell extracts were
harvested and prepared as described above. Approximately 6 × 107 F9
stem cells and 1 × 108 RA- and butyryl cAMP-treated cells were radio-
labelled.

Immunoprecipitation

Samples were diluted with distilled water to lower the salt concentration to
0.1 M NaCl. Gelatin (Difco, Detroit, MI), Triton X-100, and sodium deoxy-
cholate were then added to yield final concentrations of 2 mg/ml, 0.5 %,
and 0.5 %, respectively. Finally, preimmune antiserum (1:300) or polyclonal an-
tiserum specific for basic or FGF (1:300) was added and samples were
incubated for 1 h at 4°C with shaking. The anti–FGF antisera were directed
against synthetic peptides representing (a) amino acids 1-12 of the amino
terminus of bFGF, and (b) amino acids 59-90 of the carboxyl terminus of
aFGF. Staphylococcal protein A–Sepharose was then added to the suspen-
sion and the mixture incubated overnight at 4°C with mixing. The antigen-
antibody complexes were pelleted by centrifugation and the beads were
washed several times in PBS and finally with deionized distilled H2O before
elution directly into Na2DodSO4-PAGE sample buffer and gel electropho-
resis (Laemmli, 1970).

Western Blot Analysis

Cell extracts from 1 × 107 F9 stem cells or differentiated parietal endo-
derm prepared as described above were diluted with distilled water to lower
the salt concentration to 0.1 M NaCl. Prewashed heparin-Sepharose beads
were added to the extracts and incubated overnight at 4°C with mixing. The
beads were then washed several times with PBS, pH 7.5, and then incubated
with 1.8 ml of PBS buffer containing 0.8 M NaCl for 1 h at 4°C
with rotation. The beads were washed again in PBS, followed by two final
washes with distilled water. Proteins were eluted from the heparin-Sepharose
beads directly into Na2DodSO4-PAGE sample buffer, electrophoresed on
Na2DodSO4-15% polyacrylamide gels, and transferred electrophoretically
to BA-83 nitrocellulose paper (Transblot cell; Bio-Rad Laboratories) by de-
scribed methods (Wadzinski et al., 1987). After incubation with anti-FGF
antisera (I:1,000) for 24 h at 4°C, primary antibody binding was visualized
by serial incubations with biotinylated goat anti-rabbit antibodies, per-
oxidase-conjugated streptavidin and 4-chloro-l-naphthol (Wadzinski et al.,
1987). Additional antibodies to bFGF, raised to a synthetic peptide repres-
enting an internal portion of the molecule, amino acid residues 33-43 of
bovine bFGF, were used in these studies.

FGF Sequence-specific Probes

The cDNA probe for bovine bFGF, given to us by Dr. John Fiddes (Califor-
nia Biotechnology) was pJH1-l, which contains a 1.4-kb insert beginning
5' to a ATG 800 bp downstream of the translation stop codon (Abraham et al.,
1986). The probe for αFGF, provided by Dr. John Fiddes, was pCB1-100, which
contains a 250-bp Alu fragment of bovine genomic DNA that encodes
amino acids 1-41 of αFGF, plus a portion of an intron (Abraham et al.,
1986). Before use in Northern analysis, the cDNA and genomic inserts for
bFGF and αFGF were 32P-labeled by random hexamer priming.

Northern Analysis

F9 stem cells were plated at 1.5 × 106 cells/dish, and after an overnight in-
cubation at 37°C, RA, butyryl cAMP, and theophylline were added to some
plates as previously described (Wang et al., 1985). Poly A+ RNA was iso-
lated from F9 stem cells and from F9 cells treated for 4 d with RA and buty-
cAMP to induce differentiation as described (Wang et al., 1985) and was
analyzed by Northern blot hybridization as previously described (Wang et al.,
1985). Poly A+ RNA was also isolated from SK hepatoma cells. Hy-
bridization conditions for the cDNA probes were: 6× SSC, 0.05% sodium
pyrophosphate, 0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.1% SDS, 100
μg/ml denatured sonicated salmon sperm DNA, and 50% formamide at
42°C for 24 h. After washing the nitrocellulose blots in 2× SSC at 42°C
for the bFGF and αFGF probes, or in 1× SSC for the laminin Bl, 3J1, and
actin probes (Wang et al., 1985), the blots were exposed to Kodak XAR-5
film (Eastman Kodak, Rochester, NY) at −70°C with an intensifying
screen.

Figure 1. Heparin-Sepharose chroma-
tography of (A) cell extracts of un-
differentiated F9 stem cells; (B) cell extracts of F9 cells after
3-d treatment with RA and butyryl cAMP; (C) cell extracts; and (D)
conditioned media from fully dif-
ferentiated F9 parietal endoderm
cells, treated for 5 d with RA and butyryl cAMP. The bound proteins
were eluted by applying a linear
sodium chloride gradient (−→),
and growth factor activity was
monitored by the stimulation of
DNA synthesis in 3T3 cells (●).
Results

Heparin-binding Mitogenic Activity in F9 Stem Cells

Over the course of 2-4 d after treatment with RA and but; cAMP, F9 mouse teratocarcinoma stem cells undergo differentiation to parietal endoderm. We used the affinity of immobilized heparin for FGF to assay for these proteins in cell extracts of F9 stem cells and differentiated F9 parietal endoderm cells. Heparin-Sepharose affinity chromatography of the extracts was performed (Shing et al., 1984), and fractions assayed for stimulation of DNA synthesis in BALB/c 3T3 cells (Klagsbrun et al., 1977). This assay system is widely used for the rapid screening of a variety of growth factors, including the FGFs.

The F9 stem cell extract fractionated over heparin-Sepharose exhibited three peaks of stimulatory activities, which we have designated S1, S2, and S3 (Fig. 1 A). The largest peak (S1) was present in the void volume and accounted for $\approx 80\%$ of the stimulatory activity in the starting material.

Two other peaks of 3T3 cell stimulatory activity, representing 10% of the total activity, eluted from heparin-Sepharose at 0.25 M and 0.5 M NaCl and are designated S2 and S3, respectively. These activities have not been fully characterized but, because PDGF is known to adhere to heparin and elute with 0.5 M NaCl (Shing et al., 1984), it is probable that S3 corresponds to the intracellular pool of a PDGF-like factor that one of us has reported in the conditioned media of F9 stem cells (Gudas et al., 1983). We recovered $\approx 90\%$ of the starting mitogenic activity in the F9 stem cell extract from the heparin-Sepharose column. Approximately 1 x 10^6 stem cells yielded one unit of 3T3 cell stimulatory activity. A unit is defined as the amount of mitogen required to achieve half-maximal stimulation of DNA synthesis in the BALB/c 3T3 cell assay; maximal stimulation is obtained with addition of 20% calf serum.

Heparin-binding Mitogenic Activity in Differentiated F9 Cells

3 d after treatment with RA and but; cAMP, F9 cells were morphologically changed; they were less compact, flatter, and more triangular. The extract of RA and but; cAMP day 3 F9 cells was subjected to heparin-Sepharose chromatography and was found to contain no 3T3 cell stimulatory activity (Fig. 1 B). Thus, the activities represented by peaks S1, S2, and S3 in the undifferentiated F9 stem cells are greatly reduced, or absent by 3 d after the induction of differentiation of F9 cells into parietal endoderm.

On day 5 after induction of differentiation, the extracts from differentiated F9 parietal endoderm cells contained a new 3T3 mitogenic activity (D1), that eluted from heparin-Sepharose as a broad peak at 1.5 M NaCl (Fig. 1 C). That 1.5 M NaCl is required to elute the activity from immobilized heparin strongly suggests that it is a bFGF-like protein.

Mitogenic Activity Associated with Differentiated F9 Cells Is Not Secreted

To determine whether the activity represented by peak D1 was secreted, media conditioned by a culture of differentiated F9 parietal endoderm cells were chromatographed on heparin-Sepharose (Fig. 1 D). Results revealed no 3T3 stimulatory activity in the conditioned media, even after 10-fold concentration by heparin-Sepharose chromatography.

This is consistent with the recent reports that both basic and acidic FGF lack signal peptides (Abraham et al., 1986; Jaye et al., 1986) and that they are not secreted by cells that synthesize these factors in vitro (Vlodavsky et al., 1987b). Further, this finding distinguishes D1 from factors produced by other embryonal carcinoma cell lines, which are reportedly secreted (Heath and Isaacs, 1984), and from the potential protein product of the int-2 mRNA transcripts expressed by these cells (Yoshida et al., 1988).

Effects of F9 Cytosolic Proteins on Endothelial Cells

TGF-β does not adhere to heparin. We, therefore, suspected that S1 might be TGF-β. Because TGF-β is known to inhibit endothelial cell proliferation (Heimark et al., 1986), the S1 fractions were pooled and tested in vitro for their ability to modulate the proliferation of bovine capillary endothelial cells. S1 inhibited, in a dose-response fashion, the proliferation of capillary endothelial cells in response to recombinant bFGF (Takeda Chemical Corp., Inc., Osaka, Japan) (Table I). The inhibitory activity for bovine capillary endothelial cells was reduced by 60% by prior absorption of the cell extract with antibodies directed against TGF-β (Table I). Furthermore, prior acid treatment (Lawrence et al., 1984) of S1 increases the inhibitory activity, an indication that the latent form of TGF-β may also be present (data not shown). S1 may comprise several factors, but the above findings strongly suggest that TGF-β is at least one of the components in the S1 peak.

In contrast, the 3T3 cell mitogenic activity associated with the differentiated F9 cells eluted from the heparin-Sepharose column at a high molarity of salt, and was found to be mitogenic in a dose-response fashion for bovine capillary endothelial cells (Fig. 2). Fractions representing the D1 peak were pooled, dialyzed against PBS, tested in an endothelial cell proliferation assay (Fig. 2 A), and the results compared directly with the response of the cells to a range of doses of brain-derived heparin-purified aFGF (Fig. 2 B) and recombinant bFGF (Fig. 2 C). Each plate contained two internal controls: cells receiving PBS (Fig. 2, stippled bars) and cells receiving an identical dose, 10 mitogenic units, of recombinant bFGF (Fig. 2, solid bars). These studies were repeated several times with comparable results and a representative experiment is shown in Fig. 2.

The molarity at which D1 elutes from heparin-Sepharose

Table I. Effect of S1 on Bovine Capillary Endothelial Cell Response to bFGF

| Addition          | Cell No. (x 10^4) |
|-------------------|-------------------|
| PBS               | 1.19              |
| Basic FGF (3 ng/ml)| 13.19             |
| + S1 (1 μl/ml)    | 13.80             |
| (5 μl/ml)         | 12.89             |
| (20 μl/ml)        | 8.10              |
| (50 μl/ml)        | 2.87              |
| (100 μl/ml)       | 1.37              |
| + S1 (50 μl/ml)   |                   |
| preabsorbed with anti-TGF-β antibody | 8.49 |
Figure 2. Effect of heparin affinity-purified F9 parietal endoderm cellular extract on the proliferation of adrenal capillary endothelial cells. Capillary endothelial cells were seeded (1 x 10⁴ cells) into gelatinized 24-well tissue culture dishes and allowed to attach for 24 h in DME containing 5% calf serum. Aliquots from the pooled active fractions of the heparin-Sepharose column of F9 parietal endoderm lysates (Fig. 1, D1), dialysed against PBS, pH 7.5 (A); (B) heparin-purified brain-derived aFGF; and (C) recombinant bFGF were added at various doses to triplicate wells. Internal controls of PBS (first stippled bars) and 10-U doses of recombinant bFGF (solid bars) were included on each plate. After 72 h, cells were washed, trypsinized, and counted.

Figure 3. Expression of bFGF mRNAs. Poly A⁺ RNA (5 µg/lane) from F9 stem cells (A-C, lane 1); F9 cells treated with RA, but, cAMP, and theophylline for 4 d (A-C, lane 2); and SK hepatoma cells (A-C, lane 3). (A) bFGF cDNA probe; (B) actin cDNA probe, same blot as A; (C) laminin B1 and J31 cDNA probes. Exposure times were 3 d (bFGF), 1 h (actin), or 2 h (laminin B1 and J31). (A, large arrow) The position of the actin mRNA seen in B when this same blot was rehybridized using the actin probe. (C, arrowheads) Positions of laminin B1 mRNA at 6.2 kb (top arrowhead) and J31 mRNA at 2.2 kb (bottom arrowhead) in parietal endoderm (C, lane 2).
proteins, both cell types were analyzed for FGF content by Western blot analysis and biosynthetic labeling studies.

Several attempts using heparin-Sepharose chromatography followed by dialysis and concentration of the sample for Western analysis failed to yield reproducible results, primarily because of protein loss. To circumvent these problems, we used a modified heparin-Sepharose batch technique for the isolation of the FGFs (see Materials and Methods). Proteins from the F9 stem and differentiated F9 cell extracts that remained bound to heparin-Sepharose after washing with buffer containing 0.8 M NaCl were dissociated from the resin by boiling in Laemmli’s buffer (Laemmli, 1970), and processed for routine one-dimensional gel electrophoresis. Subsequent electrophoretic transfer (Western) blotting was performed and the nitrocellulose-bound proteins were reacted with polyclonal antibodies directed against acidic or basic FGF (Wadzinski et al., 1987) (Fig. 5).

Affinity-purified rabbit antibodies raised against peptide fragments corresponding to (a) an internal region of bFGF (amino acid residues 33–43) (Fig. 5 A, lanes I–4) and (b) the amino-terminal end (amino acid residues 1–12) of bFGF (Fig. 5 A, lanes 6–9) reacted with a single protein band of 18.4 kD from differentiated F9 parietal endoderm cells (Fig. 5 A, lanes 4 and 9). This band comigrated with bFGF derived from SK hepatoma cells, which was also recognized by these antibodies as a single, 18.4-kD protein species (Fig. 5 A, lanes 2 and 6). No immunoreaction occurred with these antibodies tested in parallel against brain-derived aFGF (Fig. 5 A, lanes 3 and 8) or proteins from F9 stem cells (Fig. 5 A, lanes I and 7).

An affinity-purified rabbit antibody, raised against the carboxy-terminal region of aFGF (amino acid residues 59–90), also reacted with differentiated F9 cell proteins, recognizing a band of ~15 kD (Fig. 5 B, lane 4). The molecular weight of this F9 protein, 15,000, corresponds to that of brain-derived aFGF recognized by this antibody as a doublet (Fig. 5 B, lane 2). There was no cross-reactivity of this antibody with SK hepatoma-derived bFGF (Fig. 5 B, lane 3) or with F9 stem cell extract tested in parallel (Fig. 5 B, lane I). The molecular weights of these proteins were calculated by comparison to Coomassie blue–prestained markers (Fig. 5 A, lane 5). These studies clearly establish the presence of factors with antigenic determinants and molecular weights characteristic of both basic and acidic FGF in cell extracts of differentiated F9 cells, not detected in F9 stem cells.

**FGFs Are Synthesized by Differentiated F9 Cells But Not by F9 Stem Cells**

Our Western blot analysis indicated the presence of both aFGF and bFGF proteins in F9 differentiated but not F9 stem cell extracts. To demonstrate synthesis of these factors, 6 × 10⁸ F9 stem and 1 × 10⁸ differentiated cells were metabolically labeled and the FGFs were immunoprecipitated using the antibodies described above. After radiolabeling with [³⁵S]methionine for 4 h, the cells were harvested and the cell extract immunoprecipitated with (a) preimmune sera, (b) the affinity-purified polyclonal antibodies against the amino-terminal end of bFGF, or (c) the affinity-purified antibodies directed against the carboxy-terminal region of aFGF (Wadzinski et al., 1987). The immunoprecipitated proteins were separated by one-dimensional Na₂DodSO₄ gel electrophoresis and autoradiographed (Fig. 6). No specific radiolabeled proteins were immunoprecipitated from F9 stem (Fig. 6, lanes I–4) or F9 differentiated (Fig. 6, lanes 5–8) cell cytosol, after a 4-h labeling, by the bFGF antibodies (Fig. 6, lanes 2 and 6) as compared with its preimmune sera (Fig. 6, lanes I and 5). A single 20–21-kD radiolabeled protein was precipitated with the aFGF antibodies from the extract of differentiated cells (Fig. 6, lane 8), which was not seen in the stem cell extract (Fig. 6, lane 4) or in the preimmune sera immunoprecipitate (Fig. 6, lanes 3 and 7). These studies indicate the presence of a newly synthesized protein, immunoreactive with an antibody specific to aFGF, only within F9 cells after differentiation.

The Western blot analysis demonstrated both acidic and basic FGF-like molecules to be present in F9 cells after differentiation. The absence of specific proteins immunoprecipitated by the antibody directed against the amino terminus of bFGF is probably due to the inability of these antibodies to effectively recognize rodent bFGF proteins in native form. One of us (T. Kurokawa) has recently determined that the amino-terminal sequence of rodent bFGF differs from that of bovine bFGF (Kurokawa et al., 1987). Rat bFGF has an amino acid deletion at residue position 9, within the region of the bovine sequence to which this antibody is raised. If mouse bFGF has the same deletion, it may be difficult to immunoprecipitate native mouse F9 cell-derived bFGF with this antibody.

**Discussion**

We have determined that F9 teratocarcinoma stem cells do not synthesize FGF, but do express this potent class of mitogens after the induction of differentiation with RA and butyrate. F9 stem cells do contain stimulatory activities for BALB/c 3T3 cells with characteristics different from FGF. The activity from the stem cells that does not bind heparin is increased by acid treatment, is inhibitory for endothelial cells (in the presence and absence of FGF) in vitro and is a potent stimulator of angiogenesis in vivo, (observations in the chick chorioallantoic membrane assay; unpublished data). The endothelial cell inhibitory activity can be partially...
removed by immunoabsorption with antibodies specific for TGF-β, suggesting that F9 stem cells synthesize a TGF-β-like activity before differentiation.

Teratocarcinoma stem cells, when placed in an aberrant position in the adult organism, form very large tumors that eventually kill their host (Martin, 1980). Folkman has proposed that all solid tumors must evoke angiogenesis, to grow beyond 1–2 mm³ in diameter (Folkman, 1963). The activity in the stem cells, which is in part TGF-β, appears to greatly decrease or disappear upon differentiation of the F9 cells in response to RA. This may prove to be an important correlate of the in vivo tumorigenicity of the undifferentiated F9 stem cells. Alternatively, the expression of TGF-β by the stem cells may be unrelated to their transformed state but rather characteristic of undifferentiated embryonic stem cells. In support of this latter hypothesis, recent studies have shown that a maternal mRNA in Xenopus eggs encoding for a TGF-β-like protein is localized to the region that eventually gives rise to embryonic endoderm cells (Weeks and Melton, 1987).

The two other minor peaks of activity derived from the extract of F9 stem cells have not been conclusively identified. The peak that elutes with 0.5 M NaCl most likely represents the intracellular PDGF-like factor that is known to be secreted by undifferentiated F9 stem cells (Gudas et al., 1983; Rizzino and Bowen-Pope, 1985). Of primary importance is the observation that none of the three activities are detected in the cytosol 3 d after the induction of differentiation. 5 d after treatment with RA and but cAMP, the differentiated F9 parietal endoderm cells synthesize an entirely new class of mitogens, the FGFs. In a preliminary study, we have examined extracts from F9 cells 7 d after treatment with RA and but cAMP and found 1.5–2 fold more FGF than on day 5. This may represent FGF that has accumulated over time, or an increased level of expression of FGF in the day 7 F9 parietal endoderm cells.

Significantly, the activity made by F9 parietal endoderm cells is not detected in conditioned media. Since lack of secretion also characterizes acidic and basic FGF this finding provides additional evidence that the differentiated F9 activity is FGF. That the F9 cell FGF-like activity is not secreted also serves to distinguish it from the int-2 and hst 1 proteins. These proteins are related to the FGFs but both have gene sequences that predict a leader signal peptide sequence that would facilitate secretion (Yoshida et al., 1987; Bovi et al., 1987).

The genes for acidic and basic FGF have been cloned (Abraham et al., 1986; Jaye et al., 1986) and a variety of cell types have been identified that synthesize bFGF (for review see Klagsbrun et al., 1986; Schweigerer et al., 1987b), but few cells have been identified that synthesize aFGF (Lobb et al., 1986). Using a bFGF cDNA probe, we detect a major mRNA of 2.2 kb in both stem and differentiated F9 cells and an additional mRNA in stem cells at 3.8 kb. Similar bFGF message sizes have been reported in human fibroblasts (Steinfeld et al., 1988). We do not know the significance of the multiple transcripts for bFGF mRNA in F9 stem cells. The genomic aFGF probe detected a 6.0–6.3-kb mRNA in parietal endoderm that was not detectable in F9 stem cells and a 5.8–6.0-kb transcript that was visible in both cell types (Fig. 4). That the size of aFGF mRNA from human brain stem (Jaye et al., 1986), differs from that in F9 cells may be due to tissue-specific differences in the processing, or species differences in mRNA size. Very few studies of aFGF mRNA are currently in the literature.

There were few differences in the steady-state levels of the major species of bFGF mRNA between the stem and parietal endoderm cells was surprising in light of the fact that there was no evidence in stem cells of FGF-like material by biological assay, biosynthetic studies, or Western blot analysis. There are at least two possible explanations for this difference. First, the stem cell mRNA may not be translated into immunoreactive or biologically active protein. This is...
A finding of consequence in this report is that factors with properties of acidic and basic FGFs are synthesized by embryonic parietal endoderm cells. The F9 cell system serves as a model for the differentiation of the mouse blastocyst, and thus our results may indicate that FGFs are present in parietal endoderm in early embryogenesis. Recent studies by Kimmelman and Kirschner (1987) have identified a mRNA encoding a bFGF-like protein in Xenopus embryos that is present throughout development, an indication that FGF may be endogenous to the developing embryo. Notably, in this system, the message abruptly increases during the midblastula transition, just before gastrulation and the development of mesoderm. What role might this class of mitogens serve in the developing embryo? In the adult, FGFs are thought to play a primary role in stimulating neovascularization during wound healing and ovulation and in association with a number of disease states. However, vascularization would not be occurring in the embryo at the time our studies indicate these FGFs would first appear. A more likely possibility is that other cell types such as epithelial cells, fibroblasts, myoblasts and chondrocytes are the targets for FGF at this point in embryonic development, as FGFs are known to stimulate the proliferation and/or differentiation of these cells. Finally, the FGFs appear likely to function as other than mitogens. FGF has been shown to induce neurite outgrowth in PC12 cells, a morphologic change associated with the differentiation of these neural cells (Togari et al., 1985; Wagner and D’Amore, 1986). Slack et al. (1987) demonstrated that bFGF and aFGF induces the formation of mesoderm in early embryonic ectodermal explants of amphibians. bFGF was shown to act as a morphogen, causing the induction of mesoderm independent of a mitogenic response. Further, the dose of FGF was critical in determining the type of mesodermal cells that resulted: low doses (2-30 ng/ml) gave rise to mesothelial and blood cells, whereas higher doses (>30 ng/ml) resulted in the formation of muscle tissue. These studies strongly suggest that FGFs can function as inducers of mesodermal tissue. Our studies implicate the parietal endoderm of the mouse embryo as one potential source of these potent inducers of various mesodermal elements.

The authors thank Michael Roguska for assistance with the Northern analysis; Dr. John Fiddes at California Biotechnology (Mountain View, CA) for the cDNA probes for acidic and basic FGF; Dr. Michael Klagsbrun for purified bFGF from SK hepatoma cells; Takeda Chemical Industries, Ltd. (Osaka, Japan) for the recombinant bFGF; Sandie Smith for purified aFGF; Paul Fanning for technical assistance with the Western analysis; Lori DeSantis for her photographic expertise; and Carlene Pavlos for assistance in the preparation of this manuscript. This work was supported by National Institutes of Health grants EY-06726 (S. J. Brahnut), EY-05985 (P. A. D’Amore) and ROI HD-24319 (L. J. Gudas). P. A. D’Amore and L. J. Gudas are Established Investigators of the American Heart Association. Received for publication 8 April 1988, and in revised form 25 January 1989.

References
Abraham, J. A., A. Mergia, J. L. Whang, A. Tumolo, J. Friedman, K. A. Hjerild, D. Gospodarowicz, and J. C. Fiddes. 1986. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science (Wash. DC). 233:545-548.
Baird, A., P. Esch, P. Bohlen, and D. Gospodarowicz. 1985. Isolation and par-

Figure 6. Autoradiogram of immunoprecipitated [35S]methionine-labeled proteins from F9 stem and parietal endoderm cells electrophoresed on a 15% NaDodSO4 polyacrylamide gel. Proteins from extracts of F9 undifferentiated stem (lanes 1–4) and F9 parietal endoderm cells (lanes 5–8) were immunoprecipitated with the premun e serum of bFGF antibody (lanes 1 and 5, respectively); or with the immune specific antibody directed against bFGF (amino acids 1-12) (lanes 2 and 6, respectively); or immunoprecipitation with the preimmune serum of the aFGF antibody (lanes 3 and 7); or with the immune sera to aFGF (amino acid residues 136-145) (lanes 4 and 8, respectively). Antibodies were used at 1:300. Molecular weights were calculated by comparison to prestained molecular weight markers (solid line) including phosphorylase b (94,000), BSA (67,000), ovalbumin (43,000), carbonic anhydrase (30,000), soybean trypsin inhibitor (21,500) and alpha-lactalbumin (14,400). (Arrowhead) Radiolabeled proteins immunoprecipitated by specific antibodies and not recognized by the preimmune serum.

A reasonable postulate since differential translation of c-myc has been similarly reported in the F9 system (Dony et al., 1985). Second, FGF may be synthesized by both the stem and differentiated cells but may not be detectable in the stem cells because of immediate consumption or degradation, whereas the cytoplasmic constituents, i.e., heparan sulfate, synthesized only by the differentiated cells may better stabilize FGF protein. This explanation is argued against by the in vivo radiolabeling data (Fig. 6), which does not demonstrate synthesis of radiolabeled FGF in stem cells, even during a relatively short labeling period. It is also possible that the 6.0-6.3-kb aFGF mRNA seen exclusively in parietal endoderm cells encode the majority of FGF in these cells.
tional characterization of an endothelial cell growth factor from bovine kidney: homology with basic fibroblast growth factor. *Regul. Pept.* 12:201–213.

Bohlen, P., A. Baird, F. Esch, N. Ling, and D. Gospodarowicz. 1984. Partial molecular characterization of pituitary fibroblast growth factor. *Proc. Natl. Acad. Sci. USA.* 81:5364–5368.

Bovi, P. D., A. M. Curatola, F. G. Kern, A. Aveco, M. Ittman, and C. Banfi. 1985. An oncogene isolated by transfection of Kapo’s Sarcoma DNA encodes a growth factor that is a member of the FGF Family. *Cell.* 50:729–737.

Burgess, W. H., T. Mehlman, R. Friesel, W. V. Johnson, and T. Maciag. 1981. Multiple forms of endothelial cell growth factor. *J. Biol. Chem.* 260:11389–11399.

Croc, C. M., A. Linnenbach, K. Huebner, J. A. Smith, and D. Gospodarowicz. 1984. Partial molecular characterization of pituitary fibroblast growth factor. *Proc. Natl. Acad. Sci. USA.* 81:5364–5368.

Bovi, P. D., A. M. Curatola, F. G. Kern, A. Aveco, M. Ittman, and C. Banfi. 1985. An oncogene isolated by transfection of Kapo’s Sarcoma DNA encodes a growth factor that is a member of the FGF Family. *Cell.* 50:729–737.

Burgess, W. H., T. Mehlman, R. Friesel, W. V. Johnson, and T. Maciag. 1981. Multiple forms of endothelial cell growth factor. *J. Biol. Chem.* 260:11389–11399.

Croce, C. M., A. Linnenbach, K. Huebner, J. A. Smith, and D. Gospodarowicz. 1984. Partial molecular characterization of pituitary fibroblast growth factor. *Proc. Natl. Acad. Sci. USA.* 81:5364–5368.

Bovi, P. D., A. M. Curatola, F. G. Kern, A. Aveco, M. Ittman, and C. Banfi. 1985. An oncogene isolated by transfection of Kapo’s Sarcoma DNA encodes a growth factor that is a member of the FGF Family. *Cell.* 50:729–737.

Croce, C. M., A. Linnenbach, K. Huebner, J. A. Smith, and D. Gospodarowicz. 1984. Partial molecular characterization of pituitary fibroblast growth factor. *Proc. Natl. Acad. Sci. USA.* 81:5364–5368.

Bovi, P. D., A. M. Curatola, F. G. Kern, A. Aveco, M. Ittman, and C. Banfi. 1985. An oncogene isolated by transfection of Kapo’s Sarcoma DNA encodes a growth factor that is a member of the FGF Family. *Cell.* 50:729–737.
Weeks, D. L., and D. A. Melton. 1987. A maternal mRNA localized to the vegetal hemisphere in xenopus eggs codes for a growth factor related to TGF-β. Cell. 51:861-867.

Yoshida, T., K. Miyagawa, H. Odagiri, H. Sakamoto, P. F. R. Little, M. Terada, and T. Sugimura. 1987. Genomic sequence of hst, a transforming gene encoding a protein homologous to fibroblast growth factors and the int-2-encoded protein. Proc. Natl. Acad. Sci. USA. 84:7305–7309.

Yoshida, T., H. Muramatsu, T. Muramatsu, H. Sakamoto, O. Katoh, T. Sugimura, and M. Terada. 1988. Differential expression of two homologous and clustered oncogenes, HST-1 and Int-2, during differentiation of P9 cells. Biochem. Biophys. Res. Commun. 157:618–625.